Analysis of the mechanism of resistrance for anticancer drugs in respect with the stroma of gastrointestinal cancer

• Project/Area Number: 15K10109
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Kagoshima University
• Principal Investigator: Sumiya ISHIGAMI 鹿児島大学, 医歯学総合研究科, 客員研究員 (90325803)
• Co-Investigator(Kenkyū-buntansha): 盛 真一郎 鹿児島大学, 医歯学域附属病院, 助教 (00620519) ; 飯野 聡 鹿児島大学, 医歯学域附属病院, 助教 (80598003)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: 消化器癌 / 抗腫瘍免疫 / 癌間質 / 抗がん剤 / 腫瘍間質 / PDL1 / 末梢血

Outline of Final Research Achievements

Immuno-checkpoint blockers anti-PD1 and PDL1 agents have been popularly administrated for advanced gastric cancer patients in Japan. It has been reported that presence of PD1 and PDL1 expression in cancer stroma affects clinical out come of these patients. In this paper we
evaluated PDL1 expression of peripheral blood in the133 gastric cancer patients by RT-PCR and clinical implication has been discussed. PDL1 expression positively correlated with the depth of the tumor and clinical stage significantly (p<0.01). High PDL1 expression group had poorer postoperative course than low expression group. PDL1expression of the peripheral blood may reflect significant immunologic marker for advanced gastric cancer.

Research Products

• [Journal Article] Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. (2018)
  • Author(s): Amatatsu M, Arigami T, Uenosono Y, Yanagita S, Uchikado Y, Kijima Y, Kurahara H, Kita Y, Mori S, Sasaki K, Omoto I, Maemura K, Ishigami S, Natsugoe S.
  • Journal Title: Cancer Sci. Volume: 109 Issue: 3 Pages: 814-820
  • DOI: 10.1111/cas.13508
  • Peer Reviewed / Open Access
• [Journal Article] Expression of gremlin1 in gastric cancer and its clinical significance (2018)
  • Author(s): Yamasaki Y, Ishigami S
  • Journal Title: Med Oncol. Volume: 35 Issue: 3 Pages: 30-30
  • DOI: 10.1007/s12032-017-1073-4
  • Peer Reviewed / Open Access
• [Journal Article] Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. (2017)
  • Author(s): Kijima T, Ishigami S
  • Journal Title: Cancer Sci Volume: 108 Issue: 2 Pages: 193-199
  • DOI: 10.1111/cas.13127
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Clinical Significance of the Glasgow Prognostic Score in Patients with Gastrointestinal Stromal Tumors. (2016)
  • Author(s): Arigami T Ishigami S
  • Journal Title: ANTICANCER RES Volume: 36 Issue: 12 Pages: 6687-6690
  • DOI: 10.21873/anticanres.11279
  • Peer Reviewed
• [Journal Article] Clinical implication of human leukocyte antigen (HLA)-F expression in breast cancer (2015)
  • Author(s): Harada A, Ishigami S
  • Journal Title: Pathol Int. Volume: １１ Issue: 11 Pages: 569-74
  • DOI: 10.1111/pin.12343
  • Peer Reviewed / Open Access